Travere Therapeutics, Inc. (TVTX)

Market Cap	2.08B
Revenue (ttm)	333.87M
Net Income (ttm)	-169.06M
Shares Out	89.14M
EPS (ttm)	-2.00
PE Ratio	n/a
Forward PE	1,500.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	829,888
Open	22.86
Previous Close	22.77
Day's Range	22.65 - 23.39
52-Week Range	12.91 - 28.69
Beta	0.79
Analysts	Strong Buy
Price Target	35.20 (+50.56%)
Earnings Date	Oct 30, 2025

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 385
• Stock Exchange: NASDAQ
• Ticker Symbol: TVTX
• Website: https://www.travere.com

Financial Performance

In 2024, Travere Therapeutics's revenue was $233.18 million, an increase of 60.55% compared to the previous year's $145.24 million. Losses were -$321.55 million, 188.6% more than in 2023.

Analyst Summary

According to 16 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price target is $35.2, which is an increase of 50.56% from the latest price.

Price Target

$35.2

(50.56% upside)

Analyst Consensus: Strong Buy